Brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to post ($1.18) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Ascendis Pharma A/S’s earnings, with the lowest EPS estimate coming in at ($1.31) and the highest estimate coming in at ($1.02). Ascendis Pharma A/S reported earnings per share of ($1.08) in the same quarter last year, which would suggest a negative year-over-year growth rate of 9.3%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 27th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full year earnings of ($3.90) per share for the current year, with EPS estimates ranging from ($4.13) to ($3.28). For the next year, analysts anticipate that the business will post earnings of ($3.49) per share, with EPS estimates ranging from ($5.50) to ($0.44). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, November 28th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.29. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.16 million.
Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its holdings in Ascendis Pharma A/S by 750.9% during the 2nd quarter. Renaissance Technologies LLC now owns 56,500 shares of the biotechnology company’s stock valued at $3,758,000 after acquiring an additional 49,860 shares during the period. Alps Advisors Inc. boosted its holdings in Ascendis Pharma A/S by 22.7% during the 3rd quarter. Alps Advisors Inc. now owns 65,448 shares of the biotechnology company’s stock valued at $4,638,000 after acquiring an additional 12,124 shares during the period. Alliancebernstein L.P. boosted its holdings in Ascendis Pharma A/S by 2.7% during the 3rd quarter. Alliancebernstein L.P. now owns 714,366 shares of the biotechnology company’s stock valued at $50,620,000 after acquiring an additional 19,039 shares during the period. Fosun International Ltd purchased a new position in Ascendis Pharma A/S during the 3rd quarter valued at about $3,544,000. Finally, FMR LLC boosted its holdings in Ascendis Pharma A/S by 24.3% during the 3rd quarter. FMR LLC now owns 4,152,262 shares of the biotechnology company’s stock valued at $294,230,000 after acquiring an additional 812,468 shares during the period. Institutional investors own 95.60% of the company’s stock.
Shares of ASND traded down $1.43 during midday trading on Friday, reaching $69.25. The company had a trading volume of 127,923 shares, compared to its average volume of 239,337. Ascendis Pharma A/S has a 1-year low of $45.17 and a 1-year high of $76.99. The company has a market capitalization of $2.94 billion, a PE ratio of -15.99 and a beta of 0.86.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
See Also: What is a Market Correction?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.